Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.33 |
| ▸ | FAP | Q12884 | 3/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29089322 | 0.82 | SLC7A5 (0.42) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL691381 | 0.80 | SLC7A5 (0.38) | DPP4DPP7FAPDPP8PREP | |
| SCHEMBL3751257 | 0.76 | KEAP1 (0.33) | — | |
| SCHEMBL4058405 | 0.76 | KEAP1 (0.33) | — | |
| SCHEMBL5875212 | 0.74 | ALDH1A1 (0.35) | — | |
| SCHEMBL5874735 | 0.74 | ALDH1A1 (0.35) | — | |
| SCHEMBL1934761 | 0.72 | KEAP1 (0.33) | — | |
| SCHEMBL17695729 | 0.70 | NFE2L2 (0.52) | — | |
| SCHEMBL20240604 | 0.69 | GSTP1 (0.33) | — | |
| SCHEMBL10992799 | 0.69 | HCAR2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368576-B2 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20060293248-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG | 2006-12-28 | — | — | US | disclosed |
| US-7109347-B2 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20050171025-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1399470-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | Probiodrug AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG (DE) | 2003-07-10 | — | — | US | disclosed |
| WO-2003002595-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293248-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | DPP4 1/4885DPP7 4/4885FAP 18/4885 |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | DPP4 1/4885DPP7 4/4885FAP 18/4885 |
| US-20050171025-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | DPP4 1/4885DPP7 4/4885FAP 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.